Form 4: Gilead CFO Andrew Dickinson Executes Stock Sale

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock.
• The transaction occurred on April 15, 2026, at a price of $140.96 per share.
• Following the sale, the reporting person retains beneficial ownership of 176,191 shares.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan, which is a standard mechanism for executive financial planning.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information or immediate market sentiment.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock appreciation, though this was a planned divestment.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance or operational outlook provided in this filing.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard corporate practice for executives to manage personal liquidity and is generally viewed as neutral by the investment community.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale represents a small fraction of the executive's total holdings.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Andrew Dickinson, CFO, Stock Sale